Inhibitors of fatty acid binding protein (FABP)
View Patent ↗The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (FABP) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below:
1. A compound, or a pharmaceutically acceptable salt of said compound, the compound being represented by the general formula I:
wherein:
Y is a ring as described below;
X is O, and
to form ring marked A is absent;
W is C(R 7 R 8 ), N(R 3 ), S, S(O 2 ), or O, and
marked ring B is absent;
G is C(R 6 );
Ring Y is aryl, heteroaryl, heterocyclyl or cycloalkyl, wherein each of said aryl, heteroaryl, heterocyclyl and cycloalkyl can be unsubstituted or optionally independently substituted with one or more substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, hydroxyl, alkyl, alkoxy, CN and CF 3 ;
R 3 may be present or absent as stated above, and when R 3 is present, R 3 is H, alkyl or cycloalkyl, wherein each of said alkyl and cycloalkyl may be unsubstituted or optionally independently substituted with one or more substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, hydroxyl, alkoxy, CN and CF 3 ;
R 1 is H, alkyl or haloalkyl;
m is 1-2;
p is 0-2;
t is 0-4;
each R 2 is independently selected from the group consisting of halo, CN, —OR 5 , alkyl, haloalkyl, haloalkoxy, aryl, heteroaryl, heterocyclyl, cycloalkyl, —NH 2 , —NH(alkyl), —NH(aryl), —NH(heteroaryl), —NH(cycloalkyl), —S-alkyl, —S-aryl, —S-heteroaryl, —S-cycloalkyl, —C(O)OH, —C(O)—NH 2 , —C(O)N(H)(alkyl), —C(O)N(H)aryl, —C(O)N(H)(heteroaryl), —C(O)N(H)(heterocyclyl), —C(O)—N(H)(cycloalkyl), —C(O)N(alkyl) 2 , —C(O)N(aryl) 2 , —C(O)N(heteroaryl) 2 , —C(O)N(heterocyclyl) 2 , —C(O)—N(cycloalkyl) 2 , —C(O)N(aryl)(alkyl), —C(O)N(heteroaryl)(aryl), —C(O)N(heterocyclyl)(heteroaryl), —C(O)N(aryl)(heterocyclyl), —C(O)—N(alkyl)(cycloalkyl), —C(O)N(cycloalkyl)(aryl), —C(O)N(cycloalkyl)(heterocyclyl), —NH—C(O)—NH 2 , —C(O)R 5 , and —C(O)OR 5 , wherein each of said alkyl, aryl, heteroaryl, heterocyclyl and cycloalkyl may be unsubstituted or optionally independently substituted with one or more substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, heteroaryl, hydroxyl, cyclalkyl, alkoxy, —C(O)R 5 , CN and CF 3 ;
Z is phenyl, wherein the phenyl may be unsubstituted or optionally independently substituted with one or more substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, CN, —OR 5 , alkyl, haloalkyl, haloalkoxy, aryl, heteroaryl, heterocyclyl, cycloalkyl, —C(O)—NH 2 , —C(O)N(H)(CH 3 ), —NH—C(O)—NH 2 , —C(O)R 5 , and —C(O)OR 5 ;
R 4 is H, alkyl, aryl or heteroaryl, wherein each of said alkyl, aryl and heteroaryl may be unsubstituted or optionally independently substituted with one or more substituents which can be the same or different, each substituents being independently selected from the group consisting of halo, hydroxyl, alkoxy, CN and CF 3 ;
R 5 is H, alkyl, cycloalkyl, aryl or heteroaryl, wherein each of said alkyl, cycloalkyl, aryl and heteroaryl may be unsubstituted or optionally independently substituted with one or more substituents which can be the same or different, each substituents being independently selected from the group consisting of halo, hydroxyl, alkoxy, —OC(O)R 4 , CN and CF 3 ;
R 6 is H;
R 7 is H, alkyl, hydroxy or alkoxy, wherein each of said alkyl and alkoxy may be independently unsubstituted or optionally independently substituted with one or more substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, hydroxyl, alkoxy, CN and CF 3 ;
R 8 is H, alkyl, hydroxy or alkoxy, wherein each of said alkyl and alkoxy may be independently unsubstituted or optionally independently substituted with one or more substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, hydroxyl, alkoxy, CN and CF 3 ;
R 9 is H, halo, alkyl, cycloalkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, alkoxyalkyl, aryloxyalkyl, heterocyclyl, carboxy or alkenyl, wherein each of said alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, aryloxy, alkoxyalkyl, alkenyl and aryloxyalkyl may be unsubstituted or optionally independently substituted with one or more substituents which can be the same or different, each substituents being independently selected from the group consisting of halo, hydroxyl, alkoxy, CN and CF 3 ; and
R 10 is H, halo, alkyl, cycloalkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, alkoxyalkyl, aryloxyalkyl, heterocyclyl, carboxy or alkenyl, wherein each of said alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, aryloxy, alkoxyalkyl, alkenyl and aryloxyalkyl may be unsubstituted or optionally independently substituted with one or more substituents which can be the same or different, each substituents being independently selected from the group consisting of halo, hydroxyl, alkoxy, CN and CF 3 ;
or alternatively, R 9 and R 10 can together form ═O or R 9 and R 10 can be joined together to form a spirocyclyl group;
R 11 is H, halo, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, hydroxyalkyl, alkoxyalkyl- or carboxy, wherein each of said alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, hydroxyalkyl, and alkoxyalkyl may be unsubstituted or optionally independently substituted with one or more substituents which can be the same or different, each substituents being independently selected from the group consisting of halo, hydroxyl, alkoxy, CN and CF 3 ; and
R 12 is H, halo, alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, hydroxyalkyl, alkoxyalkyl-, —C(O)OH, —C(O)—NH 2 , —C(O)N(H)(alkyl), —C(O)N(H)aryl, —C(O)N(H)(heteroaryl), —C(O)N(H)(heterocyclyl), —C(O)—N(H)(cycloalkyl), —C(O)N(alkyl) 2 , —C(O)N(aryl) 2 , —C(O)N(heteroaryl) 2 , —C(O)N(heterocyclyl) 2 , —C(O)—N(cycloalkyl) 2 , —C(O)N(aryl)(alkyl), —C(O)N(heteroaryl)(aryl), —C(O)N(heterocyclyl)(heteroaryl), —C(O)N(aryl)(heterocyclyl), —C(O)—N(alkyl)(cycloalkyl), —C(O)N(cycloalkyl)(aryl), —C(O)N(cycloalkyl)(heterocyclyl), —NH—C(O)—NH 2 , —C(O)R 5 , and —C(O)OR 5 , wherein each of said alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, aryloxy, hydroxyalkyl, and alkoxyalkyl may be
may be unsubstituted or optionally independently substituted with one or more substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, heteroaryl, hydroxyl, cycloalkyl, alkoxy, —C(O)R 5 , CN and CF 3 ;
or alternatively, R 11 and R 12 can together form a ═O or —R 11 and —R 12 can be joined to form a spirocyclyl group.
2. A compound, or a pharmaceutically acceptable salt of said compound, wherein the compound is selected from the group consisting of the following:
3. The compound of claim 1 wherein W is C(R 7 R 8 ).
4. The compound of claim 1 wherein W is O.
5. The compound of claim 1 wherein R 1 is H.
6. The compound of claim 1 wherein Z is phenyl.
7. A pharmaceutical composition comprising an effective amount of at least one compound of claim 1 and a pharmaceutically acceptable carrier.
8. A pharmaceutical composition comprising an effective amount of at least one compound of claim 2 and a pharmaceutically acceptable carrier.